US dispute with Pharma giant over quality control

Source: The Times
Date: 18/03/2005

The US Food and Drug Administration yesterday signalled that a dispute over manufacturing quality at GlaxoSmithKline could result in a fine and tough new compliance requirements. The FDA has been heading for a showdown with Glaxo over quality control issues at its Cidra factory since 2002, where investigators were unhappy with the manufacture of Paxil and Avandamet.

<<< Back to main page

Back to top of document